Min-Han Tan

6.6k total citations · 2 hit papers
16 papers, 2.3k citations indexed

About

Min-Han Tan is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Cancer Research. According to data from OpenAlex, Min-Han Tan has authored 16 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pulmonary and Respiratory Medicine, 12 papers in Molecular Biology and 7 papers in Cancer Research. Recurrent topics in Min-Han Tan's work include Renal cell carcinoma treatment (11 papers), Renal and related cancers (8 papers) and Cancer Genomics and Diagnostics (6 papers). Min-Han Tan is often cited by papers focused on Renal cell carcinoma treatment (11 papers), Renal and related cancers (8 papers) and Cancer Genomics and Diagnostics (6 papers). Min-Han Tan collaborates with scholars based in Singapore, United States and Denmark. Min-Han Tan's co-authors include Jessica L. Mester, Mohammed S. Orloff, Charis Eng, Lisa Rybicki, Joanne Ngeow, Frede Donskov, Christian Kollmannsberger, Daniel Y.C. Heng, Brian I. Rini and Mary J. MacKenzie and has published in prestigious journals such as Cancer Cell, The Lancet Oncology and Clinical Cancer Research.

In The Last Decade

Min-Han Tan

16 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study

2013 730 citations Daniel Y.C. Heng, Wanling Xie et al. The Lancet Oncology profile →
Lifetime Cancer Risks in Individuals with GermlinePTENMutations

2012 586 citations Min-Han Tan, Jessica L. Mester et al. Clinical Cancer Research profile →

Peers

Countries citing papers authored by Min-Han Tan

Since Specialization

Citations

This map shows the geographic impact of Min-Han Tan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Min-Han Tan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Min-Han Tan more than expected).

Fields of papers citing papers by Min-Han Tan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Min-Han Tan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Min-Han Tan. The network helps show where Min-Han Tan may publish in the future.

Co-authorship network of co-authors of Min-Han Tan

This figure shows the co-authorship network connecting the top 25 collaborators of Min-Han Tan. A scholar is included among the top collaborators of Min-Han Tan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Min-Han Tan. Min-Han Tan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	Prospective Multicenter Study Evaluating a Combined Circulating Tumor DNA and Circulating Tumor RNA Liquid Biopsy in Metastatic Non–Small Cell Lung Cancer (LIQUIK) 2025 ·JCO Precision Oncology ·Jens Samol, (unknown), Jonathan Poh, Min-Han Tan, (unknown), Jennifer Carney, James Orsini, Katherine A. Scilla, (unknown), Tan Min Chin, Chee‐Keong Toh, Boon Cher Goh, Gilberto Lopes	4
2	A Population-Based Overview of Sequences of Targeted Therapy in Metastatic Renal Cell Carcinoma 2014 ·Clinical Genitourinary Cancer ·Nimira Alimohamed, (unknown), Sandy Srinivas, Georg A. Bjarnason, Jennifer J. Knox, Mary J. MacKenzie, Lori Wood, Ulka N. Vaishampayan, Min-Han Tan, Sun Young Rha, Frede Donskov, Srinivas K. Tantravahi, Christian Kollmannsberger, Scott North, Brian I. Rini, Toni K. Choueiri, Daniel Y.C. Heng	27
3	Efficacy and Safety of an Attenuated-Dose Sunitinib Regimen in Metastatic Renal Cell Carcinoma: Results From a Prospective Registry in Singapore 2014 ·Clinical Genitourinary Cancer ·Hui Shan Tan, Huihua Li, (unknown), Chee‐Keong Toh, Alvin Wong, Gilberto Lopes, Miah Hiang Tay, Alexandre Chan, Xin Yao, Tiffany Tang, Quan Sing Ng, Ravindran Kanesvaran, (unknown), Min-Han Tan	22
4	Characteristics of Long-Term and Short-Term Survivors of Metastatic Renal Cell Carcinoma Treated With Targeted Therapies: Results From the International mRCC Database Consortium 2014 ·Clinical Genitourinary Cancer ·André P. Fay, Wanling Xie, (unknown), Lauren C. Harshman, Georg A. Bjarnason, Jennifer J. Knox, Scott Ernst, Lori Wood, Ulka N. Vaishamayan, Takeshi Yuasa, Min-Han Tan, Sun Young Rha, Frede Donskov, Neeraj Agarwal, Christian Kollmannsberger, Scott North, Brian I. Rini, Toni K. Choueiri, Daniel Y.C. Heng	12
5	Efficacy of Targeted Therapy for Metastatic Renal Cell Carcinoma in the Elderly Patient Population 2014 ·Clinical Genitourinary Cancer ·(unknown), Toni K. Choueiri, Christian Kollmannsberger, Scott North, Georg A. Bjarnason, Ulka N. Vaishampayan, Lori Wood, Jennifer J. Knox, Min-Han Tan, Mary J. MacKenzie, Frede Donskov, Brian I. Rini, Daniel Y.C. Heng	21
6	Assessment of the American Joint Committee on Cancer 7th Edition Staging for Localised Prostate Cancer in Asia Treated with External Beam Radiotherapy 2014 ·Annals of the Academy of Medicine Singapore ·Wendy Wong, (unknown), Huihua Li, Terence Tan, Ravindran Kanesvaran, Balram Chowbay, Puay Hoon Tan, Min-Han Tan, Fuh Yong Wong	4
7	The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients 2013 ·Targeted Oncology ·(unknown), Brian I. Rini, Lauren C. Harshman, Georg A. Bjarnason, Lori Wood, Ulka N. Vaishampayan, Mary J. MacKenzie, Jennifer J. Knox, Neeraj Agarwal, (unknown), Christian Kollmannsberger, Min-Han Tan, Sun Young Rha, Frede Donskov, Scott North, Toni K. Choueiri, Daniel Y.C. Heng	39
8	The Impact of Low Serum Sodium on Treatment Outcome of Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Cancer Database Consortium 2013 ·European Urology ·Fabio A.B. Schutz, Wanling Xie, Frede Donskov, Monica Sircar, David F. McDermott, Brian I. Rini, Neeraj Agarwal, Sumanta K. Pal, Sandy Srinivas, Christian Kollmannsberger, Scott North, Lori Wood, Ulka N. Vaishampayan, Min-Han Tan, Mary J. MacKenzie, Jae‐Lyun Lee, Sun Young Rha, Takeshi Yuasa, Daniel Y.C. Heng, Toni K. Choueiri	64
9	Survival Outcome and Treatment Response of Patients with Late Relapse from Renal Cell Carcinoma in the Era of Targeted Therapy 2013 ·European Urology ·Nils Kroeger, Toni K. Choueiri, (unknown), Georg A. Bjarnason, Jennifer J. Knox, Mary J. MacKenzie, Lori Wood, Sandy Srinivas, Ulka N. Vaishamayan, Sun Young Rha, Sumanta K. Pal, Takeshi Yuasa, Frede Donskov, Neeraj Agarwal, Min-Han Tan, Aristotelis Bamias, Christian Kollmannsberger, Scott North, Brian I. Rini, Daniel Y.C. Heng	55
10	External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study breakdown → 2013 ·The Lancet Oncology ·Daniel Y.C. Heng, Wanling Xie, Meredith M. Regan, Lauren C. Harshman, Georg A. Bjarnason, Ulka N. Vaishampayan, Mary J. MacKenzie, Lori Wood, Frede Donskov, Min-Han Tan, Sun Young Rha, Neeraj Agarwal, Christian Kollmannsberger, Brian I. Rini, Toni K. Choueiri	730
11	Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study 2012 ·The Lancet Oncology ·Lauren C. Harshman, Wanling Xie, Georg A. Bjarnason, Jennifer J. Knox, Mary J. MacKenzie, Lori Wood, Sandy Srinivas, Ulka N. Vaishampayan, Min-Han Tan, Sun Young Rha, Frede Donskov, Neeraj Agarwal, Christian Kollmannsberger, Scott North, Brian I. Rini, Daniel Y.C. Heng, Toni K. Choueiri	93
12	Lifetime Cancer Risks in Individuals with GermlinePTENMutations breakdown → 2012 ·Clinical Cancer Research ·Min-Han Tan, Jessica L. Mester, Joanne Ngeow, Lisa Rybicki, Mohammed S. Orloff, Charis Eng	586
13	Stage T1N0M0 renal cell carcinoma: the prognosis in Asian patients 2011 ·Chinese Journal of Cancer ·(unknown), Wei Chen, Frank Yonghong Li, Zhuowei Liu, Junhang Luo, Weber Kam On Lau, Min-Han Tan, Fang-Jian Zhou	10
14	An Antioxidant Response Phenotype Shared between Hereditary and Sporadic Type 2 Papillary Renal Cell Carcinoma 2011 ·Cancer Cell ·Aikseng Ooi, (unknown), David Petillo, Douglas H. Roossien, (unknown), Douglas Whitten, Bernice H. Wong, Min-Han Tan, Zhongfa Zhang, Ximing J. Yang, Ming Zhou, Betty Gardie, Vincent Molinié, Richard J. Kahnoski, Puay Hoon Tan, Bin Tean Teh, Kyle A. Furge	314
15	A Clinical Scoring System for Selection of Patients for PTEN Mutation Testing Is Proposed on the Basis of a Prospective Study of 3042 Probands 2010 ·The American Journal of Human Genetics ·Min-Han Tan, Jessica L. Mester, Charissa Peterson, Yiran Yang, (unknown), Lisa Rybicki, (unknown), Holly J. Pederson, (unknown), Mohammed S. Orloff, Charis Eng	289
16	Two Distinct Types of Blood Vessels in Clear Cell Renal Cell Carcinoma Have Contrasting Prognostic Implications 2007 ·Clinical Cancer Research ·Xin Yao, Chao-Nan Qian, (unknown), Min-Han Tan, Eric J. Kort, Ximing J. Yang, James H. Resau, Bin Tean Teh	76

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact